keyword
MENU ▼
Read by QxMD icon Read
search

Post metastasis prostate cancer

keyword
https://www.readbyqxmd.com/read/28528811/ability-of-a-genomic-classifier-to-predict-metastasis-and-prostate-cancer-specific-mortality-after-radiation-or-surgery-based-on-needle-biopsy-specimens
#1
Paul L Nguyen, Zaid Haddad, Ashley E Ross, Neil E Martin, Samineh Deheshi, Lucia L C Lam, Jijumon Chelliserry, Jeffrey J Tosoian, Tamara L Lotan, Daniel E Spratt, Radka S Stoyanova, Sanoj Punnen, Kaye Ong, Christine Buerki, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Kasra Yousefi, Voleak Choeurng, Elai Davicioni, Bruce J Trock, Christopher J Kane, Alan Pollack, John W Davis, Felix Y Feng, Eric A Klein
BACKGROUND: Decipher is a validated genomic classifier developed to determine the biological potential for metastasis after radical prostatectomy (RP). OBJECTIVE: To evaluate the ability of biopsy Decipher to predict metastasis and Prostate cancer-specific mortality (PCSM) in primarily intermediate- to high-risk patients treated with RP or radiation therapy (RT). DESIGN, SETTING, AND PARTICIPANTS: Two hundred and thirty-five patients treated with either RP (n=105) or RT±androgen deprivation therapy (n=130) with available genomic expression profiles generated from diagnostic biopsy specimens from seven tertiary referral centers...
May 18, 2017: European Urology
https://www.readbyqxmd.com/read/28502694/phase-ii-trial-of-the-pi3-kinase-inhibitor-buparlisib-bkm-120-with-or-without-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer
#2
Andrew J Armstrong, Susan Halabi, Patrick Healy, Joshi J Alumkal, Carolyn Winters, Julie Kephart, Rhonda L Bitting, Carey Hobbs, Colleen F Soleau, Tomasz M Beer, Rachel Slottke, Kelly Mundy, Evan Y Yu, Daniel J George
BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single arm phase II trial of buparlisib 100 mg ± enzalutamide daily in men with mCRPC whose disease progressed on or who were not candidates for docetaxel. The primary end-point was the rate of radiographic/clinical progression-free survival (PFS) at 6 months...
May 11, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28500305/nsaids-use-and-reduced-metastasis-in-cancer-patients-results-from-a-meta-analysis
#3
Xiaoping Zhao, Zhi Xu, Haoseng Li
This meta-analysis investigated the relationship between non-steroidal anti-inflammatory drugs (NSAIDs) and lymph node/distant metastasis. Relevant sources were identified from MEDLINE, EMBASE, PubMed, and Cochrane Library. Studies that reported the odds ratio (OR)/risk ratio (RR)/hazard ratio (HR) with 95% confidence intervals (CIs) for the associations of interested outcomes were included. Pooled effect estimates were obtained by using random- or fixed-effect model depending on the heterogeneity across these studies...
May 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28489571/analysis-of-stat3-post-translational-modifications-ptms-in-human-prostate-cancer-with-different-gleason-scores
#4
Rossana Cocchiola, Donatella Romaniello, Caterina Grillo, Fabio Altieri, Marcello Liberti, Fabio Massimo Magliocca, Silvia Chichiarelli, Ilaria Marrocco, Giuseppe Borgoni, Giacomo Perugia, Margherita Eufemi
Prostate Cancer (PCa) is a complex and heterogeneous disease. The androgen receptor (AR) and the signal transducer and activator of transcription 3 (STAT3) could be effective targets for PCa therapy. STAT3, a cytoplasmatic latent transcription factor, is a hub protein for several oncogenic signalling pathways and up-regulates the expression of numerous genes involved in tumor cell proliferation, angiogenesis, metastasis and cell survival. STAT3 activity can be modulated by several Post-Translational Modifications (PTMs) which reflect particular cell conditions and may be implicated in PCa development and progression...
April 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28484075/twist1-wdr5-hottip-regulates-hoxa9-chromatin-to-facilitate-prostate-cancer%C3%A2-metastasis
#5
Reem Malek, Rajendra P Gajula, Russell D Williams, Belinda Nghiem, Brian W Simons, Katriana Nugent, Hailun Wang, Kekoa Taparra, Ghali Lemtiri-Chlieh, Arum R Yoon, Lawrence True, Steven S An, Theodore L DeWeese, Ashley E Ross, Edward M Schaeffer, Kenneth J Pienta, Paula J Hurley, Colm Morrissey, Phuoc T Tran
TWIST1 is a transcription factor critical for development which can promote prostate cancer metastasis. During embryonic development, TWIST1 and HOXA9 are co-expressed in mouse prostate and then silenced post-natally. Here we report that TWIST1 and HOXA9 co-expression are re-activated in mouse and human primary prostate tumors and are further enriched in human metastases, correlating with survival. TWIST1 formed a complex with WDR5 and the lncRNA Hottip/HOTTIP, members of the MLL/COMPASS-like H3K4 methylases, which regulate chromatin in the Hox/HOX cluster during development...
May 8, 2017: Cancer Research
https://www.readbyqxmd.com/read/28477068/the-role-of-mir-130a-in-cancer
#6
REVIEW
He-da Zhang, Lin-Hong Jiang, Da-Wei Sun, Jian Li, Zhen-Ling Ji
MicroRNAs (miRs) are short and highly conserved non-coding RNAs molecules consisting of 18-25 nucleotides that regulate gene expression at post-transcriptional level by direct binding to complementary binding sites within the 3'untranslated region (3'UTR) of target mRNAs. New evidences have demonstrated that miRNAs play an important role in diverse physiological processes, including regulating cell growth, apoptosis, metastasis, drug resistance, and invasion. In chromosomes 11 and 22 of the miR-130 family, paralogous miRNA sequences, miR-130a and miR-130b are situated, respectively...
May 5, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28462855/benefits-of-using-stereotactic-body-radiotherapy-in-patients-with-metachronous-oligometastases-of-hormone-sensitive-prostate-cancer-detected-by-18f-fluoromethylcholine-pet-ct
#7
Esther W Bouman-Wammes, Joyce M van Dodewaard-De Jong, Max Dahele, Matthijs C F Cysouw, Otto S Hoekstra, R Jeroen A van Moorselaar, Maartje A H Piet, Hein J Verberne, Adriaan D Bins, Henk M W Verheul, Ben J Slotman, Daniela E Oprea-Lager, Alfons J M Van den Eertwegh
INTRODUCTION: For patients with oligometastatic recurrence of prostate cancer (PC), stereotactic body radiation therapy (SBRT) represents an attractive treatment option, as it is safe without major side effects. The aim of this study was to investigate the impact of SBRT in delaying the start of androgen deprivation therapy (ADT). PATIENTS AND METHODS: Forty-three patients treated with SBRT for oligometastatic recurrence (< 5 metastases) of hormone-sensitive PC, defined with [(18)F]fluoromethylcholine positron emission tomography/computed tomography were included...
March 29, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28385791/reader-training-for-the-re-staging-of-biochemically-recurrent-prostate-cancer-using-fluciclovine-18-f-pet-ct
#8
Matthew P Miller, Lale Kostakoglu, Daniel Pryma, Jian Qin Yu, Albert Chau, Eric Perlman, Bonnie Clarke, Donald Rosen, Penelope Ward
Fluciclovine ((18)F) is a novel positron emission tomography (PET)/computerised tomography (CT) tracer. This blinded image evaluation (BIE) sought to demonstrate that, after limited training, readers naïve to fluciclovine ((18)F), could interpret fluciclovine ((18)F) images from subjects with biochemical recurrent (BCR) prostate cancer with acceptable diagnostic performance and reproducibility. The primary objectives were to establish individual readers' diagnostic performance and the overall interpretation (2/3 reader concordance) compared to standard of truth (SOT) data (histopathology and/or clinical follow-up) and to evaluate inter-reader reproducibility...
April 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28337367/a-case-of-advanced-gastric-cancer-with-para-aortic-lymph-node-metastasis-from-co-occurring-prostate-cancer
#9
Miyeong Park, Sang-Ho Jeong, Young-Joon Lee, Ji-Ho Park, Sang-Kyung Choi, Soon-Chan Hong, Eun-Jung Jung, Young-Tae Ju, Chi-Young Jeong, Jeong-Hee Lee, Woo-Song Ha
An 84-year-old man was diagnosed with two synchronous adenocarcinomas, a Borrmann type IV advanced gastric adenocarcinoma in his antrum and a well-differentiated Borrmann type I carcinoma on the anterior wall of the higher body of his stomach. Pre-operatively, computed tomography of the abdomen revealed the presence of advanced gastric cancer with peri-gastric and para-aortic lymph node (LN) metastasis. He planned for palliative total gastrectomy owing to the risk of obstruction by the antral lesion. We performed a frozen biopsy of a para-aortic LN during surgery and found that the origin of the para-aortic LN metastasis was from undiagnosed prostate cancer...
March 2017: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/28245474/mir-543-promotes-proliferation-and-epithelial-mesenchymal-transition-in-prostate-cancer-via-targeting-rkip
#10
Yang Du, Xiu-Heng Liu, Heng-Cheng Zhu, Lei Wang, Jin-Zhuo Ning, Cheng-Cheng Xiao
BACKGROUND/AIMS: MicroRNAs (miRNAs, miRs) have emerged as important post-transcriptional regulators in various cancers. miR-543 has been reported to play critical roles in hepatocellular carcinoma and colorectal cancer, however, the role of miR-543 in the pathogenesis of prostate cancer has not been fully understood. METHODS: Expression of miR-543 and Raf Kinase Inhibitory Protein (RKIP) in clinical prostate cancer specimens, two prostate cancer cell lines, namely LNCAP and C4-2B, were determined...
2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28130102/variant-histology-and-clinicopathological-features-of-prostate-cancer-in-men-younger-than-50-years-treated-with-radical-prostatectomy
#11
Susan Prendeville, Michael E Nesbitt, Andrew J Evans, Neil E Fleshner, Theodorus H van der Kwast
PURPOSE: While prostate cancer is primarily a disease of older men, young age prostate cancer represents an important clinical subgroup which has not been adequately studied. We evaluated the histopathological features and associated clinical behavior of prostate cancer in a cohort of younger men treated with radical prostatectomy. MATERIALS AND METHODS: The study included 171 men younger than 50 years with prostate cancer who were treated with radical prostatectomy at an academic institution between 2001 and 2015...
January 24, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28063191/salvage-high-intensity-focused-ultrasound-hifu-for-locally-recurrent-prostate-cancer-after-failed-radiation-therapy-multi-institutional-analysis-of-418-patients
#12
Sebastien Crouzet, Andreas Blana, Francois J Murat, Gilles Pasticier, Stephen C W Brown, Giario N Conti, Roman Ganzer, Olivier Chapet, Albert Gelet, Christian G Chaussy, Cary N Robertson, Stefan Thuroff, John F Ward
OBJECTIVE: To report the oncological outcome of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after external beam radiotherapy (EBRT) from a multicentre database. PATIENTS AND METHODS: This retrospective study comprises patients from nine centres with local recurrent disease after EBRT treated with S-HIFU from 1995 to 2009. The biochemical failure-free survival (bFFS) rate was based on the 'Phoenix' definition (PSA nadir + 2 ng/mL)...
June 2017: BJU International
https://www.readbyqxmd.com/read/27862841/the-ubiquitin-ligase-ube4a-inhibits-prostate-cancer-progression-by-targeting-interleukin-like-emt-inducer-ilei
#13
Yanan Sun, Xiaopeng Jia, Qiang Gao, Xing Liu, Lianguo Hou
Epithelial to mesenchymal transition (EMT) is an important prerequisite for metastasis to secondary organs. Interleukin-like EMT inducer (ILEI) protein has been shown to translationally upregulated during EMT and metastatic progression as a consequence of aberrant TGF-β signaling. Our initial evaluation of FAM3C (encoding ILEI) and ILEI expression in normal prostate (PCS-440-010) and prostate cancer cell lines (DU145, LNCaP, and PC3) revealed detectable protein expression in only LNCaP cell line even though all cell lines tested had comparable FAM3C expression...
January 2017: IUBMB Life
https://www.readbyqxmd.com/read/27770303/cabazitaxel-for-hormone-relapsed-metastatic-prostate-cancer-previously-treated-with-a-docetaxel-containing-regimen-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#14
REVIEW
Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Hamilton, Duncan Chambers, Mark Clowes, John Graham, M Satish Kumar
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures cabazitaxel (Jevtana(®), Sanofi, UK) to submit evidence for the clinical and cost effectiveness of cabazitaxel for treatment of patients with metastatic hormone-relapsed prostate cancer (mHRPC) previously treated with a docetaxel-containing regimen. The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
April 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/27745980/salvage-radiation-therapy-dose-response-for-biochemical-failure-of-prostate-cancer-after-prostatectomy-a-multi-institutional-observational-study
#15
Thomas M Pisansky, Shree Agrawal, Daniel A Hamstra, Bridget F Koontz, Stanley L Liauw, Jason A Efstathiou, Jeff M Michalski, Felix Y Feng, Matthew C Abramowitz, Alan Pollack, Mitchell S Anscher, Drew Moghanaki, Robert B Den, Kevin L Stephans, Anthony L Zietman, W Robert Lee, Michael W Kattan, Andrew J Stephenson, Rahul D Tendulkar
PURPOSE: To determine whether a dose-response relationship exists for salvage radiation therapy (RT) of biochemical failure after prostatectomy for prostate cancer. METHODS AND MATERIALS: Individual data from 1108 patients who underwent salvage RT at 10 academic centers were pooled. The cohort was enriched for selection criteria more likely associated with tumor recurrence in the prostate bed (margin positive and pre-RT prostate-specific antigen [PSA] level of ≤2...
December 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27743920/development-and-validation-of-a-24-gene-predictor-of-response-to-postoperative-radiotherapy-in-prostate-cancer-a-matched-retrospective-analysis
#16
Shuang G Zhao, S Laura Chang, Daniel E Spratt, Nicholas Erho, Menggang Yu, Hussam Al-Deen Ashab, Mohammed Alshalalfa, Corey Speers, Scott A Tomlins, Elai Davicioni, Adam P Dicker, Peter R Carroll, Matthew R Cooperberg, Stephen J Freedland, R Jeffrey Karnes, Ashley E Ross, Edward M Schaeffer, Robert B Den, Paul L Nguyen, Felix Y Feng
BACKGROUND: Postoperative radiotherapy has an important role in the treatment of prostate cancer, but personalised patient selection could improve outcomes and spare unnecessary toxicity. We aimed to develop and validate a gene expression signature to predict which patients would benefit most from postoperative radiotherapy. METHODS: Patients were eligible for this matched, retrospective study if they were included in one of five published US studies (cohort, case-cohort, and case-control studies) of patients with prostate adenocarcinoma who had radical prostatectomy (with or without postoperative radiotherapy) and had gene expression analysis of the tumour, with long-term follow-up and complete clinicopathological data...
November 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27730756/risk-of-skeletal-related-events-among-elderly-prostate-cancer-patients-by-site-of-metastasis-at-diagnosis
#17
Arif Hussain, Abdalla Aly, C Daniel Mullins, Yi Qian, Jorge Arellano, Eberechukwu Onukwugha
The purpose of this study was to estimate the risk of developing skeletal-related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients. We conducted a retrospective cohort study using linked SEER (Surveillance, Epidemiology, and End Results) and Medicare data and identified men over the age of 65 with incident metastatic prostate cancer diagnosed during 2005-2009. SREs included radiation (RAD), pathological fractures (PF), bone surgery (BS), and spinal cord compression (SCC)...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27683182/a-phase-ii-trial-of-abiraterone-combined-with-dutasteride-for-men-with-metastatic-castration-resistant-prostate-cancer
#18
Rana R McKay, Lillian Werner, Elahe A Mostaghel, Rosina Lis, Olga Voznesensky, Zhenwei Zhang, Brett T Marck, Alvin M Matsumoto, Liran Domachevsky, Katherine A Zukotynski, Manoj Bhasin, Glenn J Bubley, Bruce Montgomery, Philip W Kantoff, Steven P Balk, Mary-Ellen Taplin
Purpose: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abiraterone and dutasteride.Experimental Design: Eligible patients with metastatic CRPC underwent a baseline metastasis biopsy. Patients received abiraterone and prednisone for two 4-week cycles. After this time, high-dose dutasteride (3...
February 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27681757/posttreatment-prostate-specific-antigen-6%C3%A2-months-after-radiation-with-androgen-deprivation-therapy-predicts-for-distant-metastasis-free-survival-and-prostate-cancer-specific-mortality
#19
Mihir Naik, Chandana A Reddy, Kevin L Stephans, Jay P Ciezki, Jorge Garcia, Petros Grivas, Andrew J Stephenson, Eric A Klein, Rahul D Tendulkar
OBJECTIVES/BACKGROUND: To determine whether a 6-month posttreatment prostate-specific antigen (PSA) value in patients with prostate cancer (PCa) treated with concurrent androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) serves as an early predictor for biochemical relapse free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific mortality (PCSM). METHODS: A retrospective review of intermediate-risk and high-risk PCa patients treated with EBRT and concurrent ADT at a single institution between 1996 and 2012...
November 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27670718/impact-of-single-agent-daily-prednisone-on-outcomes-in-men-with-metastatic-castration-resistant-prostate-cancer
#20
G Sonpavde, G R Pond, A J Templeton, E D Kwon, J S De Bono
BACKGROUND: Despite palliative benefits and PSA responses, the objective clinical impact of daily oral prednisone (P) for metastatic castration-resistant prostate cancer (mCRPC) is unknown. We performed a pooled analysis of control arms of randomized trials that either did or did not administer single-agent P to evaluate its impact on overall survival (OS) and toxicities. METHODS: Individual patient data from control arms of randomized trials of men with mCRPC who received placebo or P+placebo post docetaxel were eligible for analysis...
September 27, 2016: Prostate Cancer and Prostatic Diseases
keyword
keyword
76410
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"